Table 1.
Details of Patients and Controls
| Diagnosis | Case | Age (years) | Sex | DIF | IIF | Disease duration (years) | Bulbar inflammation grade (0 to 4) | Tauber stage44 (upper stage/lower stage) | Topical therapy | Systemic therapy | Other eye pathology |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Active MMP | 1 | 54 | F | IgG, IgA, C3 eye and oral | IgG 1/10 | 0.5 | 3 | IIcIIId/IIcIIId | Hypromellose, acetylcysteine, yellow soft paraffin | None | |
| 2 | 80 | M | IgG, IgA eye | IgG 1/100, IgA 1/10 | 10 | 3 | IIbIIIc(2)/IIdIIId(2) | Carmellose | Mycophenolate + dapsone | ||
| 3 | 55 | M | IgG, IgA eye | Negative | 13 | 3 | IIcIIIc(2)/IIdIIId(1) | Dexamethasone, carmellose | Mycophenolate + dapsone + deflazocort | ||
| 4 | 76 | F | IgG, IgA eye | Negative | 2 | 2.5 | IIc/IIbIIIa(2) | Prednisolone, hypromellose, carmellose | Mycophenolate + dapsone | Sicca, blepharitis | |
| 5 | 81 | M | IgG, IgA eye | IgG 1/10 | 2 | 2.5 | IIaIIIa(1)/IIbIIIb(2) | Carmellose | Mycophenolate + dapsone | ||
| 6 | 83 | M | IgG oral | Negative | 1 | 3 | IIbIIIa(1)/IIcIIIc(2) | Ofloxacin, chloramphenicol | None | ||
| 7 | 62 | F | IgG, IgA, C3 eye and oral | Negative | 18 | 2 | IIcIIIc(2)/IIdIIId(2) | Timolol, carbomer 980 | Mycophenolate | Glaucoma | |
| 8 | 64 | F | IgG, IgA vulva and mouth | ND | 1 | 2 | IIa/IIbIIIc(2) | Prednisolone | None | ||
| 9 | 83 | F | IgG, IgA oral | NC16A ELISA positive | 7 | 3 | IIa/IIbIIIb(2) | Brimonidine, latanoprost, timolol, dorzolamide, carmellose | Mycophenolate + doxycycline | Glaucoma | |
| 10 | 51 | F | IgG, IgA eye | IgG to LAD1 | 0.1 | 3 | I/IIIa(1) | None | None | ||
| Treated | 1 | 59 | F | IgG, IgA eye | Negative | 10 | 1 | IIbIIIb(2)/IIdIIId(2) | Carbomer 980 | Dapsone | |
| uninflamed MMP | 2 | 86 | F | IgG, IgA skin | IgG positive, IgG and IgA to LAD-1 | 15 | 1 | IIb/IIcIIIb(2) | None | None | |
| 3 | 78 | F | IgG, IgA oral | ND | 10 | 1 | IIbIIIb(2)/IIdIIId(2) | None | None | ||
| 4 | 84 | F | IgG, IgA eye | ND | 2 | 0 | IIb/IIcIIIc(2) | None | Mycophenolate | ||
| 5 | 66 | F | IgG, IgA eye | ND | 2 | 0 | IIb/IIcIIIb(2) | None | Dapsone | ||
| 6 | 76 | M | IgG, IgA eye | Negative | 6 | 1.5 | IIdIIId(2)/IIbIIIb(2) | Chloramphenicol, hypromellose, retinoic acid, acetylcysteine | Cyclophosphamide | ||
| 7 | 60 | F | Negative | Positive | 3 | 1 | I/IIaIIIa(1) | Carmellose | Cyclophosphamide + dapsone | ||
| Normal | 1 | 50 | F | — | 0 | — | None | None | Cataract | ||
| control | 2 | 76 | M | — | 0 | — | None | None | Cataract | ||
| 3 | 65 | M | — | 0 | — | None | None | Cataract | |||
| 4 | 70 | F | — | 0 | — | None | None | Cataract | |||
| 5 | 65 | M | — | 0 | — | None | None | Cataract | |||
| 6 | 75 | F | — | 0 | — | None | None | Cataract | |||
| 7 | 73 | F | — | 0 | — | None | None | Cataract | |||
| 8 | 57 | M | — | 0 | — | None | None | Cataract | |||
| 9 | 65 | M | — | 0 | — | None | None | Cataract | |||
| 10 | 79 | F | — | 0 | — | None | None | Cataract | |||
| 11 | 62 | M | — | 0 | — | None | None | Cataract |
DIF, direct immunofluorescence; IIF, indirect immunofluorescence, immunoblotting, and enzyme-linked immunosorbent assay results; MMP, mucous membrane pemphigoid; F, female; M, male; IgG, immunoglobulin G; IgA, immunoglobulin A; ELISA, enzyme-linked immunosorbent assay; LAD-1, Linear IgA Disease-1 protein, which is a cleavage product of bullous pemphigoid BP180 protein; ND, not done.
* Values in the IIF column include the results from immunoblotting and the ELISA.